Evotec SE

Evotec SE is a drug discovery and development company based in Germany. It operates through two main segments: Shared R&D and Just – Evotec Biologics. The company focuses on developing pharmaceutical products across a wide range of therapeutic areas, including oncology, autoimmune diseases, diabetes, heart failure, immunology, pain and inflammation, infectious diseases, kidney and liver diseases, respiratory and fibrotic conditions, metabolic diseases, rare diseases, central nervous system (CNS) disorders, cardiometabolic diseases, and animal and women's health. Evotec collaborates with numerous partners, such as Mass General Brigham, Joslin Diabetes Center, BMS, Novo Nordisk, the University of Oxford, Harvard, Yale, and many others. It also has partnerships with innovation labs like LAB282, LAB150, beLAB2122, and 65LAB.

Evotec SE is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol EVO. Its shares are traded in US dollars (USD). Although the company is headquartered in Hamburg, Germany, and operates globally, its listing on a US exchange allows investors to trade its stock in USD, making it accessible to a broad international investor base.

Evotec SE operates in the Healthcare sector and is classified under the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the research, development, and manufacturing of specialized pharmaceutical products, including both brand-name and generic drugs. As a drug discovery and development company, Evotec focuses on creating novel therapies for a variety of diseases, often through partnerships with other pharmaceutical and biotechnology firms, academic institutions, and research organizations.

Evotec SE is headquartered in Hamburg, Germany. The company was incorporated in 1993 and was formerly known as Evotec AG before rebranding in April 2019. Evotec serves a global market, including pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital firms. It has collaboration agreements with prominent organizations worldwide, such as Mass General Brigham, the University of Oxford, Harvard, Yale, Johns Hopkins University, the National University of Singapore, and others. These partnerships span multiple countries and therapeutic areas, reflecting Evotec's international reach in drug discovery and development.

Evotec SE generates revenue through its two business segments: Shared R&D and Just – Evotec Biologics. The Shared R&D segment involves collaborative research and development projects with partners, where Evotec provides its drug discovery expertise and platforms in exchange for fees, milestones, and royalties. The Just – Evotec Biologics segment focuses on biologics development and manufacturing. Notable partnerships include collaborations with Mass General Brigham and Joslin Diabetes Center for cardiometabolic diseases, BMS for antiviral therapies, Novo Nordisk for cell therapy, and the University of Oxford, German Cancer Research Center, and several other academic institutions. Evotec also has innovation lab partnerships like LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, and 65LAB. Additionally, it has a strategic collaboration with Almirall, S.A. for developing novel therapeutics for severe skin diseases.